Acetyl‐ l ‐carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Objective To detect whether oral acetyl‐ l ‐carnitine might be useful in the acute and early chronic phases of Peyronie's disease, compared with tamoxifen, a drug currently in use. Patients and methods The study included 48 patients with Peyronie's disease (15 acute and 33 initial chronic), randomized equally into two groups. The first group used tamoxifen 20 mg twice daily for 3 months and the second acetyl‐ l ‐carnitine 1 g twice daily for 3 months. The disease and stages were diagnosed and identified using a history, objective examination, pharmacologically induced erection, autophotography during erection, and basic and dynamic colour Doppler ultrasonography. Penile curvature, plaque size, pain and disease progression were assessed. The differences between the groups or between the variables before and after therapy were compared using analysis of variance or the chi‐squared test. Results Acetyl‐ l ‐carnitine was significantly more effective than tamoxifen in reducing pain and in inhibiting disease progression. Acetyl‐ l ‐carnitine reduced penile curvature significantly, while tamoxifen did not; both drugs significantly reduced plaque size. Tamoxifen induced significantly more side‐effects than acetyl‐ l ‐carnitine. Conclusions These results suggest that acetyl‐ l ‐carnitine is significantly more effective and safe than tamoxifen in the therapy of acute and early chronic Peyronie's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Autophotography in evaluation of functional penile disorders
Kelâmi, A. (1983) · Urology · doi:10.1016/0090-4295(83)90210-8 · Cited by 89
Cited by
Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials
Dambrova, M., Makrecka-Kuka, M., Kuka, J., Vilskersts, R., Nordberg, D., Attwood, M. M., Smesny, S., Sen, Z. D., Guo, A. C., Oler, E., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000408 · Cited by 507
The Management of Peyronie’s Disease: Evidence-based 2010 Guidelines
Ralph, D., Gonzalez-Cadavid, N., Mirone, V., Perovic, S., Sohn, M., Usta, M., & Levine, L. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01850.x · Cited by 324
EAU guidelines on penile curvature
Hatzimouratidis, K., Eardley, I., Giuliano, F., Hatzichristou, D., Moncada, I., Salonia, A., Vardi, Y., & Wespes, E. (2012) · European Urology · doi:10.1016/j.eururo.2012.05.040 · Cited by 309
“After 3 mo, acetyl-Lcarnitine was significantly more effective than tamoxifen in reducing pain and curvature and in inhibiting disease progression, but not in reducing penile plaque size (both tamoxifen and carnitine significantly reduced plaque size) [23].”
BackgroundThe Management of Peyronie's Disease: Evidence-based 2010 Guidelines
Shindel, A. (2011) · Yearbook of Urology · doi:10.1016/j.yuro.2010.12.007 · Cited by 300
Evidence-Based Management Guidelines on Peyronie's Disease
Chung, E., Ralph, D., Kagioglu, A., Garaffa, G., Shamsodini, A., Bivalacqua, T., Glina, S., Hakim, L., Sadeghi-Nejad, H., & Broderick, G. (2016) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2016.04.062 · Cited by 227
Metadata
- Authors
- Biagiotti, G., & Cavallini, G.
- Venue
- BJU International
- Publisher
- Wiley
- Published
- 2001-07
- Volume
- 88
- Issue
- 1
- Pages
- 63-67
- ISSN
- 1464-4096 (ISSN-L)
- 1464-410X
- OpenAlex
- W1927590389
- Cited by
- 142
- References
- 1
- FWCI
- 1.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acetyl‐ l ‐carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. https://app.cochat.ai/papers/10.1046/j.1464-410x.2001.02241.x
- The paper
- Biagiotti, G., & Cavallini, G. (2001). Acetyl‐ l ‐carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU International. https://doi.org/10.1046/j.1464-410x.2001.02241.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.